The mechanism of Erf regulation via phosphorylation-induced nucleocytoplasmic shuttling, as well as the absence of any gain-of-function ERF mutations in craniosynostosis and other Erf-related pathologies, makes Erf a worthy pharmacological target. This evidence concerns the gene ERF and craniosynostosis.